cyrilzakka/clinical-trials huggingface dataset:
Comparative Effects of Two Procedures for the Management of Posterior Shoulder Tightness

This study aims to compare the effects of a self-stretch procedures versus a clinician applied musculoskeletal procedure in individuals with posterior shoulder tightness.

Posterior shoulder mobility has been considered a contributing factor to shoulder related movement dysfunction. There is evidence indicating that posterior shoulder tightness (PST) might be present in individuals with impingement related symptoms, post-operative conditions and overhead athletes. Several studies have investigated the effects of musculoskeletal procedures (joint mobilisations and stretch) in subjects with posterior shoulder tightness (PST). This cross-over design aims to compare the differences between a well-established procedure - the crossbody stretch - versus mobilisation with movement, on range of motion and pain pressure threshold of asymptomatic individuals with unilateral PST.

Eligibility Criteria:
Inclusion Criteria:

* Asymptomatic individuals without any history of shoulder pain necessitating medical attention.
* Presence of unilateral restriction of at least 10 degrees of internal rotation deficit during the internal rotation mobility test in 90 degrees of shoulder abduction.

Exclusion Criteria:

* Asymptomatic individuals that present with shoulder pain on the assessment day.
* Individuals with chronic conditions not affecting the shoulder.
* Individuals with clinical depression.
* Individuals that used analgesic and/or anti-inflammatory medication in the previous 24 hours of assessment.
* Individuals with fibromialgia.
* Individuals engaged in overhead sports.
Effects of Epidural Local Anesthetics on Propofol Induction

The investigators designed a prospective, randomized, placebo-controlled study to determine whether thoracic epidural anesthesia(TEA) with different local anesthetics has different influences on the propofol dose during induction.


Eligibility Criteria:
Inclusion Criteria:

Surgery for thoracotomies, BMI: 18-25 Kg/m2, American Society of Anesthesiologists(ASA) classification I or II.

Exclusion Criteria:

liver or kidney disease, alcohol dependence, take sedative recently, contraindications for epidural anesthesia.
Progesterone for First Trimester Vaginal Bleeding

The purpose of this study is to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes.

First trimester vaginal bleeding is one of the most common pregnancy complications affecting 15-25% of all pregnancies. Threatened abortion is defined as bleeding through a closed cervical os in the first half of pregnancy. A subchorionic hematoma (SCH) is found in 18-39% of women with a threatened miscarriage and around 70% of women with a SCH will experience vaginal bleeding. Data on the relationship between first trimester vaginal bleeding and obstetric outcome is described mainly in retrospective and noncontrolled studies. It is hypothesized that first trimester bleeding is an indicator of a general tendency for complications (such as: preterm premature rupture of membranes (PPROM), preterm delivery (\< 37 weeks gestation; PTD) low birth weight (\<1500g; LBW) neonates, small for gestational age (SGA) neonates, placenta previa, placental abruption and stillbirth) later on in pregnancy.

Nowadays, there are not scientific based treatments for the prevention of complications associated with SCH and vaginal bleeding. Nevertheless, recent data have suggested that prophylactic administration of progesterone leads to a significant reduction in the rate of preterm deliveries and SGA neonates among patients with PTD or SGA neonates in the past. Although progesterone administration for threatened miscarriage was not studied, many physicians treat patients with first trimester vaginal bleeding with progesterone. In this era of evidence based medicine, the researchers aim to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes. The researchers hypothesize that treatment with progesterone for first trimester vaginal bleeding will alter the rates of the above mentioned obstetrical complications and adverse pregnancy outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Low risk pregnancies
* Intrauterine pregnancy documented sonographically
* Singleton pregnancy
* Known gestational age
* Healthy women

Exclusion Criteria:

* Women after reproductive assistant techniques
* Women treated with progesterone
* Multiple pregnancies
Educational Video's Impact on Knowledge Regarding Cervical Cancer Screening

The researchers will be conducting a prospective randomized trial where the researchers will be introducing an educational video to see whether there is an increase in knowledge scores surrounding cervical cancer, cervical cancer screening, and prevention with HPV vaccinations.

The researchers are conducting a single-blinded randomized controlled trial. All patients who meet exclusion criteria will be recruited at the time of their visit where a Pap smear will be collected at an ob/gyn clinic. If patients agree to participate in the study, they will be randomized into one of two arms. A control arm or an interventional arm. The control arm just includes physician counseling regarding cervical cancer screening/prevention, while the interventional arm includes patient's watching a video on cervical cancer screening/prevention as well as physician counseling. Patient will be administered a survey before and after to assess knowledge and satisfaction scores.

Eligibility Criteria:
Inclusion Criteria:

* Female patient
* Hispanic patients
* Between age 21-65 y/o
* Receiving pap smear during clinic appointment

Exclusion Criteria:

* Non-female patients
* Non-Hispanic patients
* Age less than 21
* Age greater than 65
* not receiving pap smear
Creatine for Depressed Male and Female Methamphetamine Users

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users
* Assess creatine's effect on methamphetamine use
* Assess the safety of creatine in male methamphetamine users with depression


Eligibility Criteria:
Inclusion Criteria:

* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
* Current diagnosis of major depressive disorder (primary or substance-induced)
* Current diagnosis of an anxiety disorder (primary or substance-induced)
* Current Hamilton Depression Rating scale score \> or = to 16
* Current Hamilton Anxiety Scale score \> = to 18
* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation

Exclusion Criteria:

* Persons unable to provide adequate informed consent
* Persons who are at clinically significant suicidal or homicidal risk
* Primary substance-related diagnosis other than methamphetamine dependence or abuse
* Positive pregnancy test (females only)
* History of renal disease
* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
* History of hypersensitivity reaction to creatine
Pilot Study of Regional Lung Ventilation

This is a prospective study of ventilation image comparison for lung functional information incorporation in thoracic cancer treatment planning.

Investigators hypothesize that a high resolution regional ventilation image (HRVI) based on 4D-CT imaging will correlate with the current low resolution state-of-the-art (SPECT-CT), which is the conventional way of measuring ventilation. HRVI may be a tool that could be widely used throughout the radiation therapy community because most radiation oncologists routinely employ 4D-CT technology in their own clinics. Investigators plan to test this hypothesis by comparing ventilation patterns on SPECT-CT images to HRVIs using a DICE analysis. As SPECT ventilation imaging is not included in our standard care, this study thus is designed as a pilot study.

Based on published data, the difference between the two methods for calculating the regional ventilation in the lower 50% ventilation volume is expected to have a standard deviation of about 0.1. Therefore, the 95% confidence interval for the difference in the regional ventilation between SPECT-CT and 4D-CT pre-treatment would have a width of no more than 0.14 if 10 patients are enrolled and as small as 0.10 when 20 patients are registered.

Eligibility Criteria:
Inclusion Criteria:

* Patients that have early stage non-small cell lung cancer or clinical suspicion of the same in cases where the lesion is not amenable to biopsy but is enlarging and PET-positive. All patients are to be treated with stereotactic body radiation therapy as a monotherapy.
* Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC 7th edition stage I or II based on only one of the following combinations of TNM staging:

  * T1a-b, N0, M0
  * T2a, N0, M0
  * T3 (invading the chest wall, \<5 cm in diameter) N0 M0
* Must be at least 18 years of age
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Women of childbearing potential and male participants must use an effective contraceptive method such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills.

Exclusion Criteria:

* Patients with T2b tumors or T3 tumors \>5 cm or patients with tumors involving the central chest/structures of the mediastinum;
* Primary tumor of any T-stage within or touching the zone of the proximal bronchial tree, defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi.
* Direct evidence of regional or distant metastases after appropriate staging studies
* Patients with active systemic, pulmonary, or pericardial infection;
* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
* Patients that receive chemotherapy (induction or sequential)
* Psychiatric or addictive disorders that impair subject's voluntary ability to participate in informed consent or protocol procedures
Robotic Utility for Surgical Treatment of Umbilical Hernias

The purpose of this study is the measurement of the evolution of the operation time during the start-up phase of robotic assisted surgery for the treatment of incisional hernia's of 40 patients treated in Maria Middelares in laparoscopic rTARUP technique.

Minimally invasive hernia repair by laparoscopy is the standard treatment in adult patients with an umbilical hernia larger than 2 cm in Maria Middelares, Ghent.

As previously described in a chapter in a surgical guide and in a review article on the surgical fixation technique for laparoscopic umbilical hernia repair, the used technique has been proven feasible end safe.

Robot-assisted laparoscopic surgery has become standard in urology for resection of the prostate carcinoma. In general abdominal surgery, a large group of surgeons are currently working on the introduction of robotic-assisted surgery for resection of colon and rectal cancer in their daily practice. The third generation robot (DaVinci Xi), has extended the applicability of this technology within the field of general surgery.

For the surgical treatment of hernia's and other abdominal wall defects (umbilical or/and incisional hernia's), currently only surgeons in the US have experiences in structured treatment programs.

From September 1, 2016 Maria Middelares hospital will introduce robot-assisted surgery, including the laparoscopic TARUP umbilical hernia repair.

Main obstacles to the introduction of robot technology in abdominal wall surgery are prolonged preparation time in the operating room required for installation of the robot, and higher material costs related to the robot-assisted surgery. However, there are few precise data available on the exact size of extra time or increased costs related to the introduction of robotic assisted surgery in a program for abdominal surgery.

The purpose of this study is the measurement of the evolution of the operation time during the start-up phase of robotic-assisted surgery for the treatment of umbilical hernias by 40 patients in Maria Middelares hospital.

Eligibility Criteria:
Inclusion Criteria:

* 40 patients selected and operated by the PI.

Exclusion Criteria:

* patients under the age of 18
* pregnancy
* no Informed Consent
Pilot Study of Fosamax in Spinal Cord Injury

Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months and be required to take oral fosamax versus placebo weekly.

The project was funded on August 13, 2009 and was awarded to one of our trainees, Dr. Matthew Abraham, a PGY3 in our program and our IRB approval was obtained with much time and effort on February 24, 2010. We followed the protocol and so far we recruited just one patient on September 19, 2011 who completed the study but we encountered with many unexpected obstacles to recruit any more patients to the study. The main obstacle was that the spine surgeons' refusal to start the study drug for months after surgery for fear of complications with wound healing. Secondly, the few appropriate and eligible patients we tried to recruit declined to participate.

We were unable to recruit any more patients to this study and hence the study was closed.

The one patient that was recruited completed the study. Since it is only one subject in the study, no conclusions can be drawn.

Eligibility Criteria:
Inclusion Criteria:

* American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury

Exclusion Criteria:

* History of hypersensitivity to alendronate or other bisphosphonates
* esophageal abnormality
* inability to sit/stand upright for 30 minutes
* creatinine clearance less than 35 milliliters/minute
* hypothyroidism
* malignancy
* pregnancy
* prolonged steroid use
Measurements of Facial Dimensions in Infants and Toddlers 0-4 Years of Age

Anthropometric data of infants' face will be obtained using special 3D scanners and software.

A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.

Eligibility Criteria:
Inclusion Criteria:

* Healthy infants, 0-4 years of age

Exclusion Criteria:

* Facial anomalies
A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.

To assess the efficacy and safety of salvage tratment with Gemcitabine and S-1 Combination in metastatic colorectal cancer


Eligibility Criteria:
Inclusion Criteria:

* non resectable colorectal adenocarcinoma.
* disease progression during or within 6months after treatment with irinotecan and oxaliplatin contaning regimens.
* estimated life expectancy of more than 3 months.
* ECOG status 2 or lower

Exclusion Criteria:

* other tumor type than adenoarcinoma.
* presence or history of CNS metastasis.
* evidence of gastrointestinal bleeding.
Postoperative Pain and Venipuncture Pain

Association between venipuncture pain and postoperative pain

Association will be find between venipuncture pain and postoperative pain in sleeve gastrectomy patients. Also we can study with pain catastrophising scale.

Eligibility Criteria:
Inclusion Criteria:

* sleeve gastrectomy

Exclusion Criteria:

* psychotic illness
DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

This is a 3-arm, prospective, randomized, double-blind, and controlled study of DLBS1442 for the treatment of pain in patients suspected endometriosis. It is hypothesized that the reduction of the composite-pain intensity (as measured by VAS) from baseline to the end of study (week 8th) resulting from administration of DLBS1442, regardless of the dosage regimen, is significantly greater than that of Control. In addition, the administration of DLBS1442 at higher dose also results in significantly greater reduction than that of DLBS1442 at lower dose and of Control.

There will be three groups of treatment by dosage regimen in this study. Eligible subjects will be randomized to receive any of the following regimens: 1) DLBS1442 at a dose of 3 x 100 mg daily, or 2) DLBS1442 at a dose of 3 x 200 mg daily; or 3) mefenamic acid at a dose of 3 x 500 mg daily. DLBS1442 will be taken every day along the study period (8 weeks), while mefenamic acid will only be taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period. Study treatment will be given at a standardized starting point for all subjects, i.e. on the first day of their respective menstrual periods. Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at baseline and every 4-week interval throughout the study period.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent before any trial related activities
* Female of 18 - 50 years of age
* Subjects suspected with cystic endometriosis or adenomyosis confirmed by transvaginal ultrasonography (or transrectal ultrasonography for unmarried subjects)
* Presence of moderate or severe pain as shown by VAS score of at least 4 on at least one of the following pain: menstrual pain (dysmenorrhea), dyspareunia, non-menstrual pelvic pain, dysuria, dyschezia
* Occurrence of at least 3 last sequential menstrual cycles of 21 - 35 days duration prior to screening

Exclusion Criteria:

* Pregnancy
* Patients with infertility who are willing to be pregnant
* Using hormonal contraception or other forms of hormonal therapy within the last 30 days
* Being under therapy with systemic corticosteroids on a chronic or regular basis within the last 90 days
* History or presence of suspected malignancy abnormalities
* History of surgical treatment for endometriosis within 3 months prior to screening
* History of hysterectomy or oophorectomy
* Presence of clinical signs of sexually transmitted disease
* Presence of unexplained uterine or cervical bleeding
* Impaired liver function: serum ALT \> 2.5 times upper limit of normal
* Impaired renal function: serum creatinine \>= 1.5 times upper limit of normal
* Known or suspected allergy to similar products
Role of Antibiotics Post Tonsillectomy

morbidity after tonsillictomy remains asignificant problem therefore they recommend prophylactic antibiotics to reduce it.in the other hand, the overuse of antimicrobial agents can lead to antimicrobial resistance ,adverse drug events,and unnecessary cost.so,the effectiveness and necessity of antibiotic following tonsillictomy needs to be studied .


Eligibility Criteria:
Inclusion Criteria:

200 patients who are scheduled for tonsillectomy with or without adenoidectomy, and their age are less than 18 years old of either gender will be included in our study

Exclusion Criteria:

* 1-Patients age ≥ 18 years.

  2-Trials in which antibiotics was administrated locally or used in the immediate preoperative period (within seven days before surgery).

  3. Medical comorbidity requiring treatment with antibiotics e.g. Rheumatic heart disease

  4-Patients undergoing the following procedures:
  1. Unilateral tonsillectomy or biopsy.
  2. Tonsillectomy for known carcinoma.
  3. Tonsillectomy in conjunction with palatal surgery.
  4. Hot tonsillectomy for tonsillar abscess
Non-cathartic Computed Tomographic Colonography to Screen Subjects With a Family History of Colorectal Cancer

Background: Although subjects with first-degree relatives (FDR) with a history of colorectal cancer (CRC) are at increased risk for CRC, compliance to screening colonoscopy is suboptimal. Computed tomographic colonography (CTC) has been recognized as an alternative for CRC screening in average risk subjects, but less information is available on its performance in FDRs.

Aims: To prospectively assess the accuracy of CTC as a screening tool in FDRs using colonoscopy (OC) with segmental unblinding as reference standard.

Methods: Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day. Sensitivity/specificity/PPV/NPV of CTC was assessed for detecting subjects with any lesion ≥6 mm, ≥10 mm, and for advanced neoplasia ≥6 mm.


Eligibility Criteria:
Inclusion Criteria:

* Family history for CRC (first degree)
* Age \>40 years old

Exclusion Criteria:

* Contraindications to colonoscopy or CT colonography
* Pregnancy
Single Breath Hold Abdominal MRI

The purpose of this study is to evaluate a single breath hold abdominal MRI protocol and compare the image quality of respiratory triggered 3D T1-weighted images against conventional breath hold images.


Eligibility Criteria:
Inclusion Criteria:

* undergoing abdominal MRI

Exclusion Criteria:

* none
Induce (Intellin Diabetic Foot) Feasibility Study

This is a novel feasibility study to test the participant acceptance and usability of a specifically designed smart phone app. It will also explore the effects of smart phone technology in improving self-referrals into the diabetic foot ulcer (DFU) service. Furthermore, it will be explored if this increase in self-referrals will influence the outcome of people with diabetes who have recently had a healed foot ulceration.

The rationale behind this study is if the investigators can introduce a new technology (a smart phone app) which is acceptable to patients, engages them and prompts people to take preventative health behaviours then the investigators may be able to influence the low rates of appropriate self-referral. There is evidence that links poor glycaemic control and hypertension to DFUs, so engagement in these areas of wider diabetes management needs to be reviewed, the latest National Diabetes Audit (NDA) shows only 20% of people with Type 1 and 42% of people with Type 2 diabetes achieve the 3 NICE standards for HbA1c, BP and cholesterol. In addition, healthcare providers are being asked to investigate new systems that may increase patient engagement with and the uptake of the NICE 8 annual care processes. The latest NDA shows only 40% of patients with type 1 and 60% of patients with type 2 diabetes currently have all 8 .

Eligibility Criteria:
Inclusion Criteria:

* • 18 years of age will be screened to meet the eligibility criteria:

  * Consultant or GP diagnosis of diabetes mellitus (Type I or II) , documented on the electronic patient record with HbA1C greater than 48mmol/mol
  * History of a recent diabetes foot ulcer defined as being eligible for the national diabetes foot audit and classified as healed for at least 4 weeks and no more than 12 weeks
  * Able to provide informed consent
  * Has no reasons that they could not be part of the study for 12 months such as moving out the area for attending appointments or short life expectancy from a diagnosed illness
  * Owns a smart phone

Exclusion Criteria:

* No smart phone
* Comorbidity such as poor eyesight which limits the use of smart phone
* Participation in an interventional study within the last 30 days
* Critical illness that prevents participating for a period of time